Clostridium difficile infection: new developments in epidemiology and pathogenesis
The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [45]
Citations
Cites
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“It is becoming evident from 16S ribosomal RNA sequencing that disruption of the gut microbiota following antibiotic treatment is much greater than was previously realize”
BackgroundAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Interventions to improve antibiotic prescribing practices for hospital inpatients
Davey, P., Brown, E., Charani, E., Fenelon, L., Gould, I. M., Holmes, A., Ramsay, C. R., Wiffen, P. J., & Wilcox, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003543.pub3 · Cited by 1,864
Nosocomial Acquisition of Clostridium difficile Infection
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y., & Stamm, W. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200402 · Cited by 1,326
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Glucosylation of Rho proteins by Clostridium difficile toxin B
Just, I., Selzer, J., Wilm, M., Eichel-Streiber, C. V., Mann, M., & Aktories, K. (1995) · Nature · doi:10.1038/375500a0 · Cited by 1,032
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Research works printed but not linked: 5
- Summary points on quarterly (October to December. 2008) and financial year (2007/08) acute Trust Clostridium difficile data. Key points: analyses of quarterly mandatory Clostridium difficile surveillance data. Health Protection Agency [online] , (2008).
- Thompson, A. et al. in Ninth Biennial Congress of the Anaerobe Society of Americas. PII-14 (Long Beach, California, 2008).
- Angulo, F. et al. in Second International Clostridium difficile Symposium. P5 (Maribor, Slovenia, 2007).
- Louie, T. et al. in The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. K-425a (Chicago, Illinois, 2007).
- Merrigan, M. M., Gerding, D. N. & Vedantam, G. in Eighth Biennial Conference of the Anaerobe Society of America. PI-12 (Boise, Idaho, 2006).
Cited by
Items 801–900 of 999
Clostridioides difficile infection: traversing host–pathogen interactions in the gut
Cheng, J. K. J., & Unnikrishnan, M. (2023) · Microbiology · doi:10.1099/mic.0.001306 · Cited by 22
Clostridioides difficile binary toxin CDT induces biofilm-like persisting microcolonies
Meza‐Torres, J., Tinévez, J.-Y., Crouzols, A., Mary, H., Kim, M.-H., Hunault, L., Chamorro-Rodriguez, S., Lejal, E., Altamirano-Silva, P., Groussard, D., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2444411 · Cited by 19
Immune-based treatment and prevention ofClostridium difficileinfection
Song, Z., Ghose, C., Zhang, K., Tzipori, S. R., & Sun, X. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.980193 · Cited by 19
“It is now considered the leading cause of nosocomial antibiotic-associated diarrhea (AAD) in developed countries.(5,6) The symptoms of C.”
BackgroundPathogenic C difficile is here (and everywhere) to stay
Warren, C. A., & Guerrant, R. L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61885-5 · Cited by 16
Géhin, M., Desnica, B., & Dingemanse, J. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.07.015 · Cited by 16
“in hypervirulent NAP1/027/BI strains), are considred the main virulence factors for establishment of infection [3,4].”
BackgroundIsom, C. E., Menon, S. K., Thomas, L. M., West, A. H., Richter-Addo, G. B., & Karr, E. A. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0850-0 · Cited by 22
Carvacrol reduces Clostridium difficile sporulation and spore outgrowth in vitro
Mooyottu, S., Flock, G. H., & Venkitanarayanan, K. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000515 · Cited by 19
Abadi, M. S. S., Mirzaei, E., Bazargani, A., Gholipour, A., Heidari, H., & Hadi, N. (2020) · PubMed · doi:10.7416/ai.2020.2332 · Cited by 20
“The genes encoding resistance to chloramphenicol (catD), MLS B (ermB) (17), tetracycline (tetM, tetW) (18), and metronidazole (nim) (19), were detected by PCR method using specific primers (Table 1).”
MethodBallard, J. D. (2010) · Nature · doi:10.1038/467665a · Cited by 16
Hargreaves, K. R., Otieno, J. R., Thanki, A. M., Blades, M., Millard, A. D., Browne, H. P., Lawley, T. D., & Clokie, M. R. J. (2015) · Genome Biology and Evolution · doi:10.1093/gbe/evv094 · Cited by 16
Stroke, I. L., Letourneau, J. J., Miller, T. E., Xu, Y., Pechik, I. V., Savoly, D. R., Ma, L., Sturzenbecker, L. J., Sabalski, J. E., Stein, P. D., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00107-18 · Cited by 16
“Rho-GTPases in gut epithelial cells, leading to diarrhea and colon inflammation (3).”
Background(2016) · Europe PMC (PubMed Central) · Cited by 16
Colenutt, C., & Cutting, S. M. (2014) · FEMS Microbiology Letters · doi:10.1111/1574-6968.12468 · Cited by 16
“Severe infections can lead to development of pseudomembranous colitis and toxic megacolon which is potentially fatal (Rupnik et al., 2009).”
BackgroundMicroplastics reduce soil bacterial alpha diversity and network stability
Huang, S., Huang, C., & Xiao, Y. (2026) · Soil Biology and Biochemistry · doi:10.1016/j.soilbio.2026.110085 · Cited by 16
Foschetti, D. A., Neto, M. B. B., Bolick, D. T., Moore, J., Alves, L. G. R. D. D. S. E., Martins, C., Bomfin, L., Santos, A., Leitão, R. F. D. C., Brito, G. A. D. C., et al. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20209877 · Cited by 15
Guo, S., Chen, Y., Liu, J., Zhang, X., Liu, Z., Zhou, Z. L., & Wei, W. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1943-9 · Cited by 19
Wang, J., Bakker, W., Zheng, W., de Haan, L., Rietjens, I. M. C. M., & Bouwmeester, H. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03256-8 · Cited by 16
“Glycine, CA and TCA are well known to facilitate in vitro growth of Clostridium difficile, a pathogen responsible for significant morbidity of IBD and mortality in patients (Rupnik et al. 2009; Sorg and Sonenshein 2008).”
BackgroundIcho, S., Ward, J. S., Tam, J., Kociolek, L. K., Theriot, C. M., & Melnyk, R. A. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301252120 · Cited by 17
Environmental contamination with Clostridioides (Clostridium) difficile in Vietnam
An, K. P., Phi, L. D., Bui, H. T. T., Bui, N. T., Vu, Q. T. H., Trinh, L. D., Collins, D. A., & Riley, T. V. (2023) · Journal of Applied Microbiology · doi:10.1093/jambio/lxad118 · Cited by 15
The role of gut fungi in Clostridioides difficile infection
Wang, L., Cao, Y., Lou, E., Zhao, X., & Chen, X. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100686 · Cited by 18
“The toxin produced by this bacterium has virulent effects on the colonic mucosa, resulting in reduced trans-epithelial resistance, fluid accumulation, and damage to the epithelium [22].”
BackgroundSaviano, A., Petruzziello, C., Cancro, C., Macerola, N., Petti, A., Nuzzo, E., Migneco, A., & Ojetti, V. (2024) · Microorganisms · doi:10.3390/microorganisms12010198 · Cited by 20
“Probiotics may offer an alternative and prospective strategy for the prevention and treatment of CDI [38–40].”
Clostridium Difficile Recurrent Infection: Possible Implication of TA Systems
Gil, F., Pizarro‐Guajardo, M., Álvarez, R., Garavaglia, M., & Paredes‐Sabja, D. (2015) · Future Microbiology · doi:10.2217/fmb.15.94 · Cited by 19
Barbut, F., Bouée, S., Longepierre, L., Goldberg, M., Bensoussan, C., & Lévy-Bachelot, L. (2017) · Journal of Hospital Infection · doi:10.1016/j.jhin.2017.07.006 · Cited by 15
New insights for vaccine development against Clostridium difficile infections
Pizarro‐Guajardo, M., Chamorro-Veloso, N., Vidal, R. M., & Paredes‐Sabja, D. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.04.009 · Cited by 17
Gokulan, K., Kumar, A., Lahiani, M. H., Sutherland, V. L., Cerniglia, C. E., & Khare, S. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa177 · Cited by 17
“difficile (formerly Clostridium difficile) is an anaerobic bacterium that usually resides asymptomatically in the healthy gut (Rupnik et al., 2009).”
BackgroundBanawas, S. (2022) · Antibiotics · doi:10.3390/antibiotics11091165 · Cited by 15
“The clinical signs and symptoms of CDI range from mild to severe diarrhea, which may lead to toxic megacolon, sepsis, fulminant colitis, bowel perforation, and even death [14].”
BackgroundCommunity-Acquired Clostridium Difficile Infection: Awareness and Clinical Implications
Juneau, C., Mendias, E. P., Wagal, N., Loeffelholz, M. J., Savidge, T., Croisant, S., & Dann, S. M. (2013) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2012.10.007 · Cited by 17
Otete, E. H., Ahankari, A. S., Jones, H., Bolton, K. J., Jordan, C. W., Boswell, T. C., Wilcox, M. H., Ferguson, N. M., Beck, C., & Puleston, R. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084224 · Cited by 18
“CDI results in diarrhoea which ranges in severity from mild to severe, which in life threatening cases may require surgery [1] .”
BackgroundUnderstanding and managing medication in elderly people
Lonsdale, D., & Baker, E. H. (2013) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2013.06.002 · Cited by 24
Wu, X., & Hurdle, J. G. (2014) · Canadian Journal of Microbiology · doi:10.1139/cjm-2013-0903 · Cited by 13
“For example, in the United States alone an estimated >400 000 C. difficile infections (CDIs) occur annually, resulting in >14 000 deaths (Rupnik et al. 2009; McDonald et al. 2012).”
Influentialvan Eijk, E., Paschalis, V., Green, M., Friggen, A. H., Larson, M. A., Spriggs, K. A., Briggs, G. S., Soultanas, P., & Smits, W. K. (2016) · Open Biology · doi:10.1098/rsob.160272 · Cited by 19
Li, X., Liu, J., Zhang, W., Wu, Y., Li, J., Foda, M. F., & Han, H. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c09111 · Cited by 16
Zhang, S., Yang, Q., Xu, L., Chang, J., & Sun, X. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.039 · Cited by 15
Stahlmann, J., Schönberg, M., Herrmann, M., & von Müller, L. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12558 · Cited by 16
“Most cases occur in the nosocomial setting [1].”
BackgroundIsidro, J., Mendes, A. L., Serrano, M., Henriques, A. O., & Oleastro, M. (2017) · InTech eBooks · doi:10.5772/intechopen.69053 · Cited by 24
“Disease symptoms range from mild diarrhoea and abdominal pain to life-threatening inflammatory lesions such as PMC, toxin megacolon or bowel perforation, and in severe cases sepsis and death [16, 20, 21].”
BackgroundCalderaro, A., Buttrini, M., Farina, B., Montecchini, S., Martinelli, M., Arcangeletti, C., Chezzi, C., & Conto, F. D. (2022) · Microorganisms · doi:10.3390/microorganisms10071477 · Cited by 14
“difficile infection (CDI) ranges from mild, self-limiting diarrhoea to severe outcomes such as fulminant colitis, toxic megacolon, bowel perforation, and sepsis [3,4].”
BackgroundPal, R., & Seleem, M. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267859 · Cited by 16
“difficile infection (CDI), toxin A (TcdA) and toxin B (TcdB), the clinical sequelae of which ranges from mild or moderate diarrhea to severe complications characterized by fulminant colitis, toxic megacolon, sepsis, and even death [6, 7].”
BackgroundDiscovery of Selective Inhibitors of the Clostridium difficile Dehydroquinate Dehydratase
Ratia, K. M., Light, S. H., Antanasijevic, A., Anderson, W. F., Caffrey, M. S., & Lavie, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089356 · Cited by 14
“difficile infection (CDI) is treatment with a broad-spectrum antibiotic to combat a preexisting bacterial infection [1].”
BackgroundBoseiwaqa, L. V., Foster, N. F., Thean, S. K., Squire, M. M., Riley, T. V., & Carson, K. C. (2013) · Pathology · doi:10.1097/pat.0b013e3283632680 · Cited by 14
Infecciones causadas por Clostridium difficile: una visión actualizada
Hernández-Rocha, C., Naour, S., Álvarez-Lobos, M., & Paredes‐Sabja, D. (2012) · Revista chilena de infectología · doi:10.4067/s0716-10182012000400011 · Cited by 24
Toxicity assessment of Clostridium difficile toxins in rodent models and protection of vaccination
Wang, S., Rustandi, R. R., Lancaster, C., Hong, L., Thiriot, D. S., Xie, J., Secore, S., Kristopeit, A., Wang, S., & Heinrichs, J. H. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.026 · Cited by 14
Abuderman, A., Mateen, A., Syed, R., & Aloahd, M. S. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.04.013 · Cited by 14
“difficile are well established source for transmission [9,10].”
BackgroundTime-resolved transcriptome analysis of Clostridium difficile R20291 response to cysteine
Gu, H., Shi, K., Liao, Z., Qi, H., Chen, S., Wang, H., Li, S., Ma, Y., & Wang, J. (2018) · Microbiological Research · doi:10.1016/j.micres.2018.07.003 · Cited by 15
The mechanisms and safety of probiotics against toxigenic clostridium difficile
Liu, D., Zeng, L., Yan, Z., Jia, J., Gao, J. X., & Wei, Y. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1778464 · Cited by 18
Giron, M. C., & Mazzi, U. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.11.002 · Cited by 14
Invisible steps for a global endemy: molecular strategies adopted by Clostridioides difficile
Fettucciari, K., Marconi, P., Marchegiani, A., Fruganti, A., Spaterna, A., & Bassotti, G. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211032797 · Cited by 15
Dawood, A., Zuberi, A., & Shi, W. (2022) · Journal of Applied Animal Research · doi:10.1080/09712119.2021.2018327 · Cited by 14
“Good evidence of this causal relationship has been provided by a study conducted on a mouse infected with Clostridium difficile (Rupnik et al. 2009).”
BackgroundBarbut, F., Ramé, L., Petit, A., Suzon, L., de Chevigny, A., & Eckert, C. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2014.09.021 · Cited by 20
Bintz, J., Lenhart, S., & Lanzas, C. (2016) · Bulletin of Mathematical Biology · doi:10.1007/s11538-016-0224-7 · Cited by 14
“Antibiotics disrupt the intestinal microbiota, which facilitates the colonization of Clostridium difficile (Rupnik et al., 2009).”
BackgroundPituch, H. M., Obuch-Woszczatyński, P., Lachowicz, D., Kuthan, R., Dzierżanowska‐Fangrat, K., Mikucka, A., Jermakow, K., Pituch, A., & Davies, K. (2018) · Advances in Medical Sciences · doi:10.1016/j.advms.2018.03.003 · Cited by 14
Sasaki, D., Sasaki, K., Kadowaki, Y., Aotsuka, Y., & Kondo, A. (2019) · AMB Express · doi:10.1186/s13568-019-0911-5 · Cited by 16
Surviving Between Hosts: Sporulation and Transmission
Swick, M. C., Koehler, T. M., & Driks, A. (2016) · ASM Press eBooks · doi:10.1128/9781555819286.ch20 · Cited by 19
Fecal Transplant for Recurrent Clostridium difficile Infection
Lofland, D., Josephat, F., & Partin, S. (2013) · American Society for Clinical Laboratory Science · doi:10.29074/ascls.26.3.131 · Cited by 13
Overview of Clostridium difficile infection: implications for China
Chen, X., & LaMont, J. T. (2013) · Gastroenterology report · doi:10.1093/gastro/got029 · Cited by 14
“About 25% of patients treated with metronidazole or vancomycin will suffer a recurrence after treatment is discontinued; many of these will have multiple recurrences [26].”
BackgroundSensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains
Beran, V., Chmelař, D., Vobejdová, J., Konigova, A., Nemec, J., & Tvrdík, J. (2013) · Folia Microbiologica · doi:10.1007/s12223-013-0283-1 · Cited by 13
“Recently published information on the outbreaks of diarrheal diseases in health care facilities whose etiological agents were hypervirulent strains ofC. difficile ribotype 027 are coming fromCanada, USA and Europe (McDonald et al. 2006; Gravel et al. 2009; Rupnik et al. 2009).”
BackgroundSubinhibitory Concentrations of LFF571 Reduce Toxin Production by Clostridium difficile
Sachdeva, M., & Leeds, J. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04436-14 · Cited by 13
“Approximately 500,000 cases occur in the United States each year, making CDI the most common hospital-acquired infection (1, 2).”
BackgroundHarvala, H., Alm, E., Åkerlund, T., & Rizzardi, K. (2016) · New Microbes and New Infections · doi:10.1016/j.nmni.2016.09.002 · Cited by 13
“Clostridium difficile, a Gram-positive and spore-forming anaerobic bacillus, is a leading cause of healthcare-associated diarrhoea in industrialized countries [1].”
BackgroundJiménez, A., Araya, R., Hidalgo, D. P., Camacho-Mora, Z., Du, T., Golding, G. R., Astorga, G. L., Rodríguez, C., & Quesada-Gómez, C. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.03.027 · Cited by 13
Dowson, L., Bennett, N. J., Buising, K. L., Marshall, C. L., Friedman, N. D., Stuart, R. L., & Kong, D. C. M. (2019) · American Journal of Infection Control · doi:10.1016/j.ajic.2019.08.034 · Cited by 13
Zhao, N., Luo, Y., Bian, Q., Wang, L., Ye, J., Song, X., Jiang, J., Tang, Y., Wang, X., & Jin, D. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s238916 · Cited by 13
Akiyama, S., Yamada, A., Komaki, Y., Komaki, F., Micić, D., & Sakuraba, A. (2020) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001330 · Cited by 13
Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines
Khurana, S., Kahl, A., Yu, K., & Dupont, A. W. (2020) · Faculty Reviews · doi:10.12703/b/9-13 · Cited by 15
Wu, Z., Xu, Q., Gu, S., Wang, Q., Chen, Y., Lv, L., Zheng, B., Wang, K., Wang, S., Xia, J., et al. (2022) · Food & Function · doi:10.1039/d2fo00374k · Cited by 18
Clostridioides difficile infection: microbe-microbe interactions and live biotherapeutics
Wang, R. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1182612 · Cited by 14
“difficile results in various outcomes: from no colonization to asymptomatic carriages, from mild diarrhea to life-threatening complications (Rupnik et al., 2009; Crobach et al., 2018).”
BackgroundUltrastructure of Clostridium difficile colonies
Lipovšek, S., Leitinger, G., & Rupnik, M. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.09.014 · Cited by 18
Diagnosis of Clostridium Difficile Infection: The Molecular Approach
Eckert, C., Jones, G., & Barbut, F. (2013) · Future Microbiology · doi:10.2217/fmb.13.129 · Cited by 13
Plaza-Garrido, Á., Miranda-Cárdenas, C., Castro-Córdova, P., Olguín-Araneda, V., Cofré-Araneda, G., Hernández-Rocha, C., Carman, R. J., Patricio Ibáñez, L., Fawley, W. N., Wilcox, M. H., et al. (2015) · Anaerobe · doi:10.1016/j.anaerobe.2015.09.005 · Cited by 14
Kouzegaran, S., Ganjifard, M., & Tanha, A. (2016) · Materia Socio Medica · doi:10.5455/msm.2016.28.324-328 · Cited by 13
“Clostridium difficile is an important cause of antibioticassociated diarrhea and one of the most common healthcareassociated infections al-around the world (2, 3).”
BackgroundZhang, Y., Yang, Z., Gao, S., Hamza, T., Yfantis, H. G., Lipsky, M., & Feng, H. (2017) · Anaerobe · doi:10.1016/j.anaerobe.2017.10.006 · Cited by 15
“These arguments led to a hypothesis that the differential effects of TcdB in animal and human intestines may be due to the expression of toxin receptors [15].”
BackgroundHorvat, S., Mahnič, A., Breskvar, M., Džeroski, S., & Rupnik, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15434-1 · Cited by 16
Chowdhury, P. R., DeMaere, M. Z., Chapman, T. A., Worden, P. J., Charles, I. G., Darling, A. E., & Djordjevic, S. P. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0653-3 · Cited by 15
“difficile infections range from being asymptomatic to causing mild or severe diarrhoea and occasionally lifethreatening conditions such as pseudomembranous colitis and toxic megacolon [1, 5].”
BackgroundFaecal microbiota transplantation—A clinical view
Mattner, J., Schmidt, F., & Siegmund, B. (2016) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2016.02.003 · Cited by 12
Maslanka, J. R., Gu, C. H., Zarin, I., Denny, J. E., Broadaway, S. C., Fett, B., Mattei, L. M., Walk, S. T., & Abt, M. C. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1851999 · Cited by 13
“difficile to grow.(4,5) Upon establishment of infection, C.”
BackgroundFan, J., Cui, H., Mu, Z., Yao, C., Yang, M., Jin, Y., Ning, C., & Zhang, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-71516-x · Cited by 15
“Clostridium is a medically significant genus that includes pathogens that cause several diseases in adults and children, such as C. difficile and C. perfringens , which cause antibiotic-associated diarrhea and colitis 35,36 .”
BackgroundBlau, K., & Gallert, C. (2024) · Pathogens · doi:10.3390/pathogens13110965 · Cited by 16
Janežič, S., Indra, A., Allerberger, F. J., & Rupnik, M. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.031054-0 · Cited by 12
“Clostridium difficile, the causative agent of antimicrobialassociated diarrhoea and pseudomembranous colitis, is currently one of the most important nosocomial pathogens (Rupnik et al., 2009).”
BackgroundMethodViazis, N., Pontas, C., Κarmiris, K., Dimas, I., Fragaki, M., Paspatis, G. A., Drygiannakis, I., Κoutroubakis, I. E., Moschovis, D., Tzouvala, M., et al. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001414 · Cited by 12
Metzendorf, N. G., Lange, L. M., Lainer, N., Schlüter, R., Dittmann, S., Paul, L.-S., Troitzsch, D., & Sievers, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.814692 · Cited by 14
Clostridioides (Clostridium) difficile in children with diarrhoea in Vietnam
An, K. P., Phi, L. D., Pham, P. T., Thu, H. N. T., Vu, Q. T. H., Collins, D. A., & Riley, T. V. (2022) · Anaerobe · doi:10.1016/j.anaerobe.2022.102550 · Cited by 12
Clostridioides difficile Binary Toxin Binding Component Increases Virulence in a Hamster Model
Simpson, M. D., Bilverstone, T. W., Leslie, J. L., Donlan, A. N., Uddin, M. J., Petri, W. A., Marin, N., Schwan, C., Kuehne, S., Minton, N. P., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad040 · Cited by 12
“In the past few decades, researchers have seen an overall increase in both the frequency and severity of CDI, a phenomenon that has been primarily associated with the emergence of hypervirulent strains of C difficile [6].”
BackgroundDunisławska, A., Pietrzak, E., Bełdowska, A., Sławińska, A., & Siwek, M. Z. (2023) · Journal of Animal and Feed Sciences · doi:10.22358/jafs/156098/2023 · Cited by 13
“C. difficile is a Gram-positive anaerobic, spore-forming bacteria belonging to the phylum Firmicutes of the family Clostridiaceae (Rupnik et al., 2009).”
BackgroundPerras, C., Tsakonas, E., Ndegwa, S., Conly, J. M., Valiquette, L., & Farrah, K. (2011) · Cited by 12
Recombination Drives Evolution of the Clostridium difficile 16S-23S rRNA Intergenic Spacer Region
Janežič, S., Indra, A., Rattei, T., Weinmaier, T., & Rupnik, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106545 · Cited by 12
“65 years), community-acquired infection is being increasingly reported [1–3].”
BackgroundChallenges and opportunities for faecal microbiota transplantation therapy
Rogers, G. B., & Bruce, K. D. (2013) · Epidemiology and Infection · doi:10.1017/s0950268813001362 · Cited by 14
“This trend is, in part, related to the emergence of certain strains that are hypervirulent and antibiotic resistant [29].”
BackgroundWei, C., Wen-En, L., Yang-Ming, L., Shan, L., & Yi-Ming, Z. (2015) · PubMed Central · doi:10.5114/aoms.2015.54846 · Cited by 12
“The morbidity, mortality and relapse rates of disease caused by CD have markedly increased in many parts of the world in the past decade [7, 8], and CD is now recognized not only as one of the major causes of serious healthcare-associated infections [9], but also as a community acquired infection [10, 11].”
Makristathis, A., Zeller, I., Mitteregger, D., Kundi, M., & Hirschl, A. M. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-2916-9 · Cited by 12
Yu, K., Bi, N., Xiong, C., Cai, S., Long, Z., Guo, Z., & Gu, G. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b01242 · Cited by 12
Novel Chimeric Protein Vaccines Against Clostridium difficile Infection
Wang, S., Wang, Y., Cai, Y., Kelly, C. P., & Sun, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02440 · Cited by 14
Castro-Córdova, P., Díaz-Yáñez, F., Muñoz-Miralles, J., Gil, F., & Paredes‐Sabja, D. (2020) · Anaerobe · doi:10.1016/j.anaerobe.2020.102149 · Cited by 13
Vitucci, J. C., Pulse, M., Tabor‐Simecka, L., & Simecka, J. W. (2020) · BMC Microbiology · doi:10.1186/s12866-020-1710-5 · Cited by 13
Aubry, A. J., Zou, W., Vinogradov, E., Williams, D., Chen, W., Harris, G., Zhou, H., Schur, M. J., Gilbert, M., Douce, G. R., et al. (2020) · Vaccines · doi:10.3390/vaccines8010073 · Cited by 12
Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile
Karyal, C., Hughes, J., Kelly, M. L., Luckett, J., Kaye, P., Cockayne, A., Minton, N. P., & Griffin, R. (2021) · Microorganisms · doi:10.3390/microorganisms9020306 · Cited by 15
Effective Barriers: The Role of NKT Cells and Innate Lymphoid Cells in the Gut
Cairo, C., & Webb, T. J. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100799 · Cited by 11
“Clostridium difficile infection can cause severe colitis and diarrhea when the normal microbiota is perturbed after antibiotic treatment (149).”
BackgroundMichel, A., Acuña, J. M. B., Molinari, G., Ünal, C., Will, S. E., Derksen, E., Barthels, S., Bartram, W., Schrader, M., Rohde, M., et al. (2022) · Environmental Microbiology · doi:10.1111/1462-2920.15925 · Cited by 11
Blau, K., & Gallert, C. (2023) · Antibiotics · doi:10.3390/antibiotics12010162 · Cited by 13
Jayaratne, P., Monkman, L., Broukhanski, G., Pillai, D. R., & Lee, C. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.002 · Cited by 12
Queraltó, C., Ortega, C., Díaz-Yáñez, F., Inostroza, O., Espinoza, G., Álvarez, R., González, R., Parra, F., Paredes‐Sabja, D., Acuña, L. G., et al. (2023) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2023.05.004 · Cited by 13
Design of 8-mer peptides that block Clostridioides difficile toxin A in intestinal cells
Sarma, S., Catella, C. M., Pedro, E. T. S., Xiao, X., Durmusoglu, D., Menegatti, S., Crook, N., Magness, S. T., & Hall, C. K. (2023) · Communications Biology · doi:10.1038/s42003-023-05242-x · Cited by 10
Montazeri, N., Liu, D., & Janes, M. E. (2015) · Food and Nutrition Sciences · doi:10.4236/fns.2015.611110 · Cited by 11
“difficile transmitted through person-to-person contacts or the environment [1] [2].”
BackgroundUngurs, M. J., Wand, M. E., Vassey, M., O‘Brien, S., Dixon, D., Walker, J. T., & Sutton, J. M. (2011) · American Journal of Infection Control · doi:10.1016/j.ajic.2010.07.015 · Cited by 11
Metadata
- Authors
- Rupnik, M., Wilcox, M. H., & Gerding, D. N.
- Affiliations
- University of Maribor (SI)
- Leeds General Infirmary (GB)
- Loyola University Chicago (US)
- Venue
- Nature Reviews Microbiology
- Published
- 2009-07
- Volume
- 7
- Issue
- 7
- Pages
- 526-536
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1968953113
- Cited by
- 1,380
- References
- 124
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 49 · 2023: 59 · 2022: 74 · 2021: 72 · 2020: 88 · 2019: 78 · 2018: 109 · 2017: 104 · 2016: 107 · 2015: 107 · 2014: 133 · 2013: 141 · 2012: 93
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- Clostridium difficile infection, nosocomial infections, virulence factors, epidemiology, pathogenesis, community-acquired infections, food-producing animals, antibiotic-associated diarrhea, clinical outcomes, infection prevention and treatment
- MeSH terms
- Animals, Anti-Bacterial Agents, Enterocolitis, Pseudomembranous, Humans, Models, Theoretical, Clostridioides difficile, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.